Optimizing therapy: benefits of combining omeprazole with calcium carbonate
Abstract
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly inhibiting the parietal cell H+/K+ ATPase pump its effects begin with in 1 hour, peak at 3 hours, and last approximately 72 hours. Omeprazole is administered via delayed release formulations (capsules, tablets) to protect it from stomach acid, achieving 30-40% bioavailability. It undergoes hepatic metabolism primarily via CYP2C19 & CYP3A4, with a plasma half-life of 0.5-1 hour. Dosing includes 80mg daily for GERD (up to 8 weeks) and 20mg twice daily in H-pylori eradication triple therapy. Calcium carbonate acts as an antacid by neutralizing gastric acid (HCL) via dissociation into calcium ions & carbonate anions, which buffer H+ ions. It also serves as a calcium supplement & phosphate binder. Absorption occurs in the small intestine & is enhanced by food and stomach acidity. Most body calcium is stored in bones or teeth, with excretion via Feces (unabsorbed) and urine formulations include tablets, chewable and suspensions. Dosing ranges from 500-1000mg for heartburn (max 7g/day) & 1-2 g/day for Ca2+ supplementation. Omeprazolesuppresses gastric acid secretion, which is essential for solubilizing insoluble calcium salts like calcium carbonate. This acid suppression significantly reduces the bioavailability of calcium from based supplements, while the combination is not contra indicated. When you take omeprazole for a long time & also take calcium carbonate needsstomach acid to break down and get into your body. So, taking them together means your body might not absorb the calcium well. This is especially important for people taking omeprazole long-term who need calcium for bone health. Omeprazole provides long-acting suppression of stomach acid production by inhibiting the proton pumps in the stomach lining. It’s used for conditions like GERD, peptic ulcers & erosive esophagitis. Calcium carbonate offers rapid, short-term neutralization of existing stomach acid. It’s commonly used for immediate relief of heart burn and indigestion. While sometimes used together for enhanced symptom control calcium carbonate can interfere with omeprazole absorption if taken simultaneously. Therefore, dosing typically requires separating administration.
Keywords:
Omeprazole, H+/K+ATPase, CYP2C19 & CYP3A4, GERD (gastroesophagealrefluxdisease), H-pylori (helicobacterpylori), Calcium carbonate, Erosive esophagitisDOI
https://doi.org/10.70604/References
1. Sachs, G., Shin, J. M., & Howden, C. W. (2006). The clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 23(2),2-8.
2. Andersson, T., & Weidolf, L. (2008). Stereoselective disposition of proton pump inhibitors. Clinical Drug Investigation, 28(5),263-279.
3. Robinson, M. (2001). Review article: The pharmacodynamics and pharmacokinetics of proton pump inhibitors—focus on omeprazole. Alimentary Pharmacology & Therapeutics, 15(Suppl 2),2-10.
4. Rost, K. L., & Roots, I. (1994). Accelerated omeprazole metabolism in extensive metabolizers of sparteine. Clinical Pharmacology & Therapeutics, 55(6),630-635.
5. Katz, P. O., Gerson, L. B., & Vela, M. F. (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. The American Journal of Gastroenterology, 108(3),308-328.
6. Howden, C. W., & Hunt, R. H. (1990). The relationship between suppression of acidity and gastric ulcer healing rates. Alimentary Pharmacology & Therapeutics, 4(1), 25–33.
7. Metz, D. C. (2000). Diagnosis and treatment of Zollinger–Ellison syndrome in the era of PPIs. Best Practice & Research Clinical Gastroenterology, 15(3), 467–484.
8. Talley, N. J., Vakil, N., & Moayyedi, P. (2005). American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology, 129(5), 1756–1780.
9. Osman M, Yadlapati R. (2022). Antacids revisited: a review of basic science and clinical utility. Journal of Clinical Gastroenterology, 56(9), 767–774.
10. Gruyaert B, et al. (2021). Onset of acid-neutralizing action of calcium/magnesium carbonate-based antacid using an artificial stomach model.BMC Gastroenterology, 21-64.
11. Wood RJ, Serfaty-Lacrosnière C. (1992). Gastric acidity, calcium absorption, and calcium carbonate supplements. Nutrition Reviews, 50(11):301–306.
12. Sheikh MS, et al. (1989). Reduction of dietary phosphorus absorption by phosphate binders. Journal of Clinical Investigation, 83(1):66–73.
13. Heaney RP, Recker RR, Weaver CM. (1990). Absorbability of calcium sources: the limited role of solubility. Osteoporosis International, 1(2):65–67.
14. Bommer J, et al. Calcium load during CaCO₃ administration in healthy individuals; impact on urinary calcium excretion. Nephrol Dial Transplant. 2008;23(9):2861–2866.
15. Penniston KL, et al. (2008). Excess calcium carbonate ingestion and recurrent kidney stones. Urological Research, 36(2):77–81.
16. Beall DP, Scofield RH. (1995). Milk-alkali syndrome associated with calcium carbonate consumption – Report of 7 patients with review of literature. Medicine (Baltimore), 74(2):89–96.
Published
Abstract Display: 1440 
PDF Downloads: 165 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
.